Company: IMRX
Filing Date: 2025-09-24
Form Type: 8-K
Source: 0001104659-25-092957
Chunk: 1

Company: Immuneering Corp
Filing Date: 2025-09-24
Form: 8-K
Item: Item 1.01
Chunk 1
---
 or an affiliate of the Company (a “ Change of Control”) or any other license,
sale, assignment, transfer, grant or other disposition of the Company’s or an affiliate of the Company’s rights to research,
develop, manufacture, commercialize, or otherwise exploit atebimetinib (a “ Covered Transaction” and, collectively, a “ Strategic
Transaction Process”), (ii) provide the Investor the opportunity to participate in such Strategic Transaction Process subject to
customary confidentiality and other undertakings on substantially the same procedural terms and timeframe as other participants, and (iii)
for a period of 120 days following the date of the Purchase Agreement, not enter into any Covered Transaction or commence, continue, or
otherwise engage in any discussions, or negotiate with any third party, to enter into any Covered Transaction (provided that this provision
shall not limit the entry by the Company into, or any engagement in discussion or negotiations with any third party regarding, a Change
of Control transaction). These provisions contain customary confidentiality restrictions and limitations on disclosure obligations, and
will terminate upon the earlier of: (a) such time as the Investor and its affiliates no longer hold at least 50% of the securities purchased
from the Company pursuant to the Purchase Agreement, (b) 90 days after the public release of the topline results of the overall survival
of the Phase 3 clinical trial of atebimetinib in pancreatic cancer, (c) the liquidation, dissolution or winding-up of the affairs of the
Company, or the consummation of any Change of Control or any other deemed liquidation event of the Company and (d) such time as all development
activities with respect to atebimetinib have been terminated.

In addition, pursuant to the Purchase Agreement, the Investor agreed
(i) until the date that is six months after the closing date of the Private Placement, to be subject to customary lock-up restrictions
with respect to sales of shares of the Company’s Common Stock (or similar transactions with the same economic effect), subject to
certain customary exceptions, (ii) until the first anniversary of the closing date of the Private Placement, to be subject to stand-still
restrictions with respect to acquisitions of shares of the Company’s Common Stock and similar activities, subject to certain customary
exceptions and fall-away provisions, and (iii) until the first anniversary of the closing date of the Private Placement or such earlier
time as the stand-still restrictions shall have fallen away, vote with respect to